Need Assistance?
  • US & Canada:
    +
  • UK: +

TB500

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

TB500, a synthetic version of the active region of thymosin β4, has been reported to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and reduce inflammation.

Category
Peptide Inhibitors
Catalog number
BAT-009371
CAS number
885340-08-9
Molecular Formula
C38H68N10O14
Molecular Weight
889.01
TB500
Size Price Stock Quantity
50 mg $299 In stock
100 mg $399 In stock
IUPAC Name
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid
Synonyms
N-Acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln; N-acetyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-alpha-glutamyl-L-threonyl-L-glutamine; Thymosin Beta 4 Peptide 500
Appearance
White Lyophilized Powder
Purity
>98%
Density
1.281±0.06 g/cm3 (Predicted)
Boiling Point
1405.0±65.0°C (Predicted)
Sequence
Ac-LKKTETQ
Storage
Store at -20°C
Solubility
Soluble in Water (50 mg/mL)(56.24 mM, Need ultrasonic)
InChI
InChI=1S/C38H68N10O14/c1-19(2)18-27(42-22(5)51)35(58)44-23(10-6-8-16-39)32(55)43-24(11-7-9-17-40)33(56)47-30(20(3)49)36(59)45-25(13-15-29(53)54)34(57)48-31(21(4)50)37(60)46-26(38(61)62)12-14-28(41)52/h19-21,23-27,30-31,49-50H,6-18,39-40H2,1-5H3,(H2,41,52)(H,42,51)(H,43,55)(H,44,58)(H,45,59)(H,46,60)(H,47,56)(H,48,57)(H,53,54)(H,61,62)/t20-,21-,23+,24+,25+,26+,27+,30+,31+/m1/s1
InChI Key
ADKDNDYYIZUVCZ-ZQNQAVPYSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C
1. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs
Vivian Delcourt, Patrice Garcia, Benjamin Chabot, Agnès Barnabé, Maëlle Bouscarel, Benoit Loup, Marie-Agnès Popot, Ludovic Bailly-Chouriberry Drug Test Anal. 2022 Dec 8. doi: 10.1002/dta.3421. Online ahead of print.
Nowadays, numerous websites attempt to commercialize over the internet various products, regardless of the lack of approval by the EMA or the FDA either for human or veterinary use. These products are often produced after aborted drug development due to insufficient or deleterious biological effects, synthesized based on natural products, or only based on scientific literature. However, the administration of such products is dangerous, considering the lack of official control over the production of these substances and the absence of approval by health authorities. In this short communication, we provide an extensive analysis of three misbranded and adulterated products sold over the internet named TB500, TB1000, and SGF1000. We confirm that the content of TB500/TB1000 products is not systematically consistent with it's former descriptions, but also that SGF1000 is mainly composed of sheep extracellular matrix (ECM) and blood proteins, and the signal corresponding to the purported growth promoters is excessively diluted.
2. Multi-analyte screening of small peptides by alkaline pre-activated solid phase extraction coupled with liquid chromatography-high resolution mass spectrometry in doping controls
Jing Jing, Tian Tian, Yang Wang, Xin Xu, Yuanhong Shan J Chromatogr A. 2022 Aug 2;1676:463272. doi: 10.1016/j.chroma.2022.463272. Epub 2022 Jun 22.
Peptidic drugs with wide spectrum of physiological activity are of interest for cheating athletes and can be misused as doping in sports. A growing number of small peptide drugs capable of enhancing performance are included in the prohibited list issued by World Anti-Doping Agency (WADA), therefore the improvement of the detection methods is constantly needed. In the present study, a screening assay was developed comprising 54 prohibited small peptides and the related substances in urine by means of the alkaline pre-activated weak cation exchange-solid phase extraction (WCX-SPE) with liquid chromatography-high resolution mass spectrometry (LCHRMS). This method performed good enrichment and purification effect of traditional WCX for basic peptides, and also improve the purification power of acidic peptides, which significantly expanded the coverage of detection substances. The method was validated in accordance with WADA relevant criteria and validated with a main focus on qualitative parameters including selectivity, limits of detection (0.02-0.2 ng/mL), linearity (0.1-20 ng/mL for 46 analytes and 0.2-20 ng/mL for 9 analytes), accuracy and precision (RE% and RSD% < 20% at 1, 5 and 10 ng/mL), recovery (39.2%-100.1% except for the TB500(1-2) free acid: 9.2%), matrix effects (ion suppression effect: 0 to 49.4% and ion enhancement effect: 100% and 264.6%), carryover, reliability and sample extract stability. As a proof-of-principle, urine samples from two patients received a single injection of leuprorelin acetate microspheres (3.75 mg) 30 days before were analyzed and the results proved the applicability of the method.
3. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls
Mario Thevis, Wilhelm Schänzer J Pharm Biomed Anal. 2014 Dec;101:66-83. doi: 10.1016/j.jpba.2014.05.020. Epub 2014 May 23.
The number and diversity of potentially performance-enhancing substances is continuously growing, fueled by new pharmaceutical developments but also by the inventiveness and, at the same time, unscrupulousness of black-market (designer) drug producers and providers. In terms of sports drug testing, this situation necessitates reactive as well as proactive research and expansion of the analytical armamentarium to ensure timely, adequate, and comprehensive doping controls. This review summarizes literature published over the past 5 years on new drug entities, discontinued therapeutics, and 'tailored' compounds classified as doping agents according to the regulations of the World Anti-Doping Agency, with particular attention to analytical strategies enabling their detection in human blood or urine. Among these compounds, low- and high-molecular mass substances of peptidic (e.g. modified insulin-like growth factor-1, TB-500, hematide/peginesatide, growth hormone releasing peptides, AOD-9604, etc.) and non-peptidic (selective androgen receptor modulators, hypoxia-inducible factor stabilizers, siRNA, S-107 and ARM036/aladorian, etc.) as well as inorganic (cobalt) nature are considered and discussed in terms of specific requirements originating from physicochemical properties, concentration levels, metabolism, and their amenability for chromatographic-mass spectrometric or alternative detection methods.
Online Inquiry
Verification code
Inquiry Basket